US biopharmaceutical firms currently have 395 drugs and vaccines to fight infectious diseases in clinical trials or under review by the US Food and Drug Administration, according to a report from the Pharmaceutical Research and Manufacturers of America.

The group also found that scientists are also working on treatments for diseases more commonly associated with the developing world, including the Ebola virus and cholera.

US companies are working on 18 new medications and vaccines to treat staph infections and sepsis, 145 vaccines to prevent infections such as influenza, 88 antibiotics and 96 antivirals.

HIV/AIDS treatments have not been included in the report, although a 2009 survey indicated that 97 medicines were in testing.